Literature DB >> 17258818

Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1.

Ding-Kwo Chang1, Chang-Sheng Hsu.   

Abstract

Two HIV-1 gp41-derived peptide fusion inhibitors, T-20 and T-649, were synthesized and their binding profiles of the N-heptad repeat region (HR1) were compared to examine the molecular basis of the differential antiviral potency and viral resistance. Turbidity clearance experiments based on the overlapping 15-mer peptides derived from HR1 revealed a major binding site at the LLSGIV segment for both T-20 and T-649. Additionally, another docking site was found at the sequence encompassing the hydrophobic pocket of HR1 for T-649. Concordant results were observed from the surface plasmon resonance measurements. The binding affinity profile exhibited a major maximum around the LLSGIV motif for the two peptide fusion inhibitors while a less prominent docking region was located near the hydrophobic pocket for T-649. This bi-modal model deduced from T-20 and T-649 interaction with HR1 peptides could rationalize the failure of emergence of the fusion inhibitor-resistant virus with simultaneous mutations in each of the two binding regions, as well as the generally higher potency of T-649 against most viral strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258818     DOI: 10.1016/j.antiviral.2006.12.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

Authors:  Yuxian He; Jianwei Cheng; Hong Lu; Jingjing Li; Jie Hu; Zhi Qi; Zhonghua Liu; Shibo Jiang; Qiuyun Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

Review 2.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

3.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

Review 4.  Peptides in the treatment of AIDS.

Authors:  Fred Naider; Jacob Anglister
Journal:  Curr Opin Struct Biol       Date:  2009-07-23       Impact factor: 6.809

5.  Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

Authors:  Yuxian He; Jianwei Cheng; Jingjing Li; Zhi Qi; Hong Lu; Mingxin Dong; Shibo Jiang; Qiuyun Dai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

6.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Authors:  Josh D Nelson; Heather Kinkead; Florence M Brunel; Dan Leaman; Richard Jensen; John M Louis; Toshiaki Maruyama; Carole A Bewley; Katherine Bowdish; G Marius Clore; Philip E Dawson; Shana Frederickson; Rose G Mage; Douglas D Richman; Dennis R Burton; Michael B Zwick
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

7.  The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide.

Authors:  Eran Noah; Zohar Biron; Fred Naider; Boris Arshava; Jacob Anglister
Journal:  Biochemistry       Date:  2008-06-10       Impact factor: 3.162

8.  Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures.

Authors:  Isabella Bon; David Lembo; Marco Rusnati; Alberto Clò; Silvia Morini; Anna Miserocchi; Antonella Bugatti; Sonia Grigolon; Giuseppina Musumeci; Santo Landolfo; Maria Carla Re; Davide Gibellini
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.